KOR

e-Article

Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study
Document Type
Clinical report
Source
BMC Cancer. Jan 13, 2009, Vol. 9, p14
Subject
France
Language
English
ISSN
1471-2407
Abstract
Background We explored the heterogeneity of philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL) in a study of the effect of early features on prognosis in children. Here we report the long-term results of the FRALLE 93 study conducted in the era before the use of tyrosine kinase inhibitors. Methods Between 1993 and 1999, 36 children with Ph1-ALL were enrolled into the FRALLE 93 protocol. After conventional four-drug induction, children were stratified by availability of an HLA-matched sibling. Results Complete remission (CR) was observed in 26 children (72%), of which 13 underwent allogeneic bone marrow transplantation (BMT). Thirty-one children were good responders to prednisone, defined on day 8, and 21 were good responders to chemotherapy, defined by day-21 bone marrow (M1). Overall five-year disease-free survival (DFS) was 42 [+ -] 9.7%. Based on multivariate analysis, two groups showed marked differences in five-year outcome: children with age[less than]10, leukocyte count [less than]100,000/mm.sup.3 .sup.and day-21 M1 marrow had a more favorable prognosis (14 pts: 100% CR, event free survival [EFS]: 57%, overall survival [OS]: 79%), than the high-risk group (22 patients: 55% CR, EFS: 18%, OS: 27%) (p [less than] 0.005). We also observed a non statistically significant difference (p = 0.14) in outcome between these groups for transplanted patients (5-year DFS: 83 [+ -] 14% and 33 [+ -] 15%, respectively). Conclusion Age, leukocyte count and early response to treatment defined by the D21 bone marrow response provide an accurate model for outcome prediction. The combination of available tools such as minimal residual disease assessment with determination of these simple factors could be useful for refining indications for BMT in the current era of tyrosine-kinase inhibitor-based therapy.
Authors: Virginie Gandemer (corresponding author) [1]; Marie-Francoise Auclerc [2]; Yves Perel [3]; Jean-Pierre Vannier [4]; Edouard Le Gall [1]; Francois Demeocq [5]; Claudine Schmitt [6]; Christophe Piguet [7]; Jean-Louis Stephan [...]